- Case report
- Open Access
Pneumomediastinum as a complication of SABR for lung metastases
© Rodriguez-Ruiz et al. ; licensee BioMed Central. 2015
- Received: 1 August 2014
- Accepted: 7 January 2015
- Published: 23 January 2015
Stereotactic ablative body radiation (SABR) is a novel and sophisticated radiation modality that involves the irradiation of extracranial tumors through precise and very high doses in patients with oligometastatic lung disease and primary lung tumors.
A 52-year-old female with subclinical idiopathic interstitial lung disease (ILD) and oligometastatic lung disease from squamous urethral cancer who was treated with SABR for a metastatic lesion located in the right lower pulmonary lobe. The patient received a hypo-fractionated course of SABR. A 3D-conformal multifield technique was used with six coplanar and one non-coplanar statics beams. A 48 Gy total dose in three fractions over six days was prescribed to the 95% of the PTV. The presence of idiopathic ILD and other identifiable underlying lung conditions were not taken into account as a constraint to prescribe a different than standard total dose or fractionation schedule. Six months after the SABR treatment, a CT-scan showed the presence of a pneumomediastinum with air outside the bronchial tree and within the subcutaneous tissue without co-existing pneumothorax. To our knowledge, this is the first case of pneumomediastinum appearing 6 months after SABR treatment for a lung metastasis located in the perihiliar/central tumors region as defined by the RTOG protocols as the proximal bronchial tree.
Radiation oncologist should be aware of the potential risk of severe lung toxicity caused by SABR in patients with ILD, especially when chemotherapy-induced pulmonary toxicity is administered in a short time interval.
- Oligometastatic lung disease
- SABR (stereotactic ablative body radiation)
- SBRT (stereotactic beam radiation therapy)
Stereotactic ablative body radiation (SABR) is a novel and sophisticated radiation modality that involves the irradiation of extracranial tumors using precise and very high doses of radiation delivered in one to five fractions. This modality has been used in the treatment of non-metastatic primary cancer and also in the case of oligometastases . Phase I/II studies data from patients with oligometastatic lung disease who were treated with SABR or SBRT (stereotactic body radiation therapy), seem to be very promising with high local control rates and long-term survivors in properly selected patients [2,3].
SABR for lung metastases can produce several lung toxicities, such as airways collapse, atelectasis, symptomatic pneumonitis, fibrosis and pathological vertebral fracture . The incidence of symptomatic radiation pneumonitis or grade 3–4 pneumonitis is low, in the range of 0-5% . The risk of pneumonitis is associated with the type of chemotherapy regimen previously administrated, dosimetric parameters, and patient’s age. Non-pulmonary adverse effects, such as esophagitis, esophageal stenosis, massive hemoptysis, pleural effusion and pericardial effusion have been described in patients treated with SABR. The development of these adverse events depend on the location of the tumor and the dose regimen used. A phase II study conducted at Indiana University observed excessive toxicities in 70 patients with central and perihiliar lung tumors treated with high doses of radiation delivered during SBRT (60–66 Gy in three fractions) . In their cohort, twenty percent of patients experienced severe toxicity, including decline in pulmonary function tests, pleural effusion, and pneumonia. Authors informed of 6 treatment-related deaths, the majority of which were due to pneumonia. Moreover, patients with central tumors showed an 11-fold increased risk of presenting a severe toxicity compared to patients with peripheral lesions.
To our knowledge, we report the first case of pneumomediastinum appearing 6 months after treatment with SABR for a solitary lung metastasis located in the perihiliar/central tumors region defined by the RTOG protocols as the proximal bronchial tree.
A 52-year-old woman with idiopathic interstitial lung disease was referred to our department in March 2010 for a second opinion regarding a metastatic urethral carcinoma. Her history began one year ago when she noticed a node in the urethral meatus by self-palpation associated with perineal pain. Magnetic Resonance (MR) images demonstrated a 2 x 1.5 cm urethral nodule with urethral thickening including the trigone and a single iliac lymph node of 1.2 cm of diameter. A cystoscopy with biopsy revealed a well differentiated infiltrating epidermoid urethral cancer with positive surgical margins. Staging CT-scans were performed showing no distant metastatic disease. On July 2010, the patient underwent anterior pelvic exenteration, urostomy with ileal bladder reconstruction and vaginal reconstruction with a transverse rectus abdominis myocutaneous (TRAM) flap.
The disease was followed until November 2010, when the physical examination demonstrated the presence of a nodule of 3 cm in the right subvaginal space and bilateral metastatic inguinal lymph nodes. The positron emission tomography/computed tomography (PET-CT) revealed tumor recurrence near of the neovagina, the presence of bilateral inguinal lymph nodes and a single lung metastases. A fine-needle aspiration biopsy was obtained from inguinal lymph nodes and the pathologic study confirmed lymph node metastasis of squamous-cell carcinoma of the urethra. The patient was initially treated with six cycles of chemotherapy using paclitaxel 175 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1 and capecitabine 750 mg/m2 on days 1–15 every 21 days. Complete clinical response was observed after six cycles of chemotherapy.
Between March and May 2011, a consolidation hypofractionated course of IMRT (intensity-modulated radiation therapy) was delivered using the step-and-shoot technique. The IMRT dose administrated was 62 Gy prescribed to the 95% of the clinical target volume (CTV = urethra and inguino-pelvic lymph node (LN) in 25 fractions, 2.48 Gy/fraction. Three cycles of chemotherapy with paclitaxel 50 mg/m2 and Cisplatin 30 mg/m2 on a weekly regimen were concomitantly given throughout the whole course of IMRT. IMRT was followed by a short course of high-dose-rate (HDR) intravaginal brachytherapy. A dose of 4.75 Gy was prescribed at minimum target dose (MTD), over three consecutive days with a total dose of 19 Gy.
The development of novel and sophisticated irradiation techniques such as SABR represents a progress in planning and delivering external beam radiotherapy. SABR delivers large doses of radiation in few fractions, and it has been demonstrated to be a safe, effective and promise ablative technique for the treatment of selected patients with lung metastases. Patients diagnosed of oligometastatic lung disease who are considered inoperable or patients that are not candidates for surgical treatment, SABR emerges as a practical option. The reported 2-year overall survival ranges from 67% to 100% and the 2-year local control rate has been established between 92% and 95% .
We present the first case of SABR-induced pneumomediastinum in a patient with a solitry lung metastasis and subclinical interstitial lung disease (ILD). A total dose of 48 Gy in three fractions over six days was administered to the 95% of the PTV (Figures 3-4). The PTV, which includes setup uncertainty and residual target motion was designed from the GTV by enlarging the volume 0.5 cm in the axial plane and 1.0 cm in the cranial-caudal plane in all directions. In this particular case, we discard abdominal compression to reduce respiratory motion because comparing free breathing and abdominal compression there was no differences in tumor motion.
Radiation pneumonitis (RP) is one of the most significant complications for patients treated with SBRT  and fatal radiation toxicity has been reported in patients with centrally-located stage I lung cancer . Timmerman et al. described six SBRT-related deaths in patients with inoperable stage I lung cancer treated with 60–66 Gy in three fractions during 1–2 weeks. The causes of death were pneumonia, pericardial effusion and massive hemoptysis.
Subclinical ILD was not found to be a significant factor for grade 2–5 RP or clinical outcomes in a recent Japanese study where 100 patients with 124 lung tumors were treated with SABR. Patients with subclinical (untreated and oxygen-free) ILD were treated with SABR (48 Gy in four fractions), while those with clinical ILD (post- or under treatment) were not. However, a significant finding was the presence of uncommon extensive RP in patients with subclinical ILD . Our patient was previously diagnosed of subclinical ILD and she presented pneumomediastinum confirmed by the presence of free air in the mediastinal structures 6 months after SBRT. Another risk factor in this patient associated with severe toxicity is the administration of very high doses of radiation in three fractions (16 Gy x 3) in a lesion located in the perihiliar region. In the other hand, we think that the presence of idiopathic ILD and other lung disease should be taken into account as a more restrictive constraint trying to achieve a BED > =100 Gy. These selected patients can be treated with 4 to 10 fractions risk-adapted SABR regimens.
To our knowledge, pneumomediastinum has not been associated as a complication related to SABR of a primary lung cancer or lung metastasis. Pneumomediastinum was described in the early 19th century by the pathologist R. T. Läennec, who first observed this condition in trauma patients . Primary or spontaneous pneumomediastinum (SPM) is caused by increased pressure gradient between the alveoli and pulmonary interstitium. SPM represents approximately 1% of all cases of pneumomediastinum (PM) and is generally a benign process that mainly affects young people, especially male smokers . Underlying lung conditions as asthma, ILD (loss of integrity of the alveolar-capillary membrane), pneumonia, bullous lung, and radiation therapy for lung cancer have all been associated with SPM . ILD has been identified as the most frequent predisposing factor to PM . Franquet et al.  found SPM in 4 patients of 78 patients (5.1%) with idiopathic pulmonary fibrosis. They assessed the presence and distribution of pulmonary parenchymal abnormalities on CT images at the time of detection of pneumomediastinum, and the author observed parenchymal abnormalities such as ground-glass attenuation or honeycombing pattern with a subpleural predominant distribution.
In a study of 34 patients with interstitial pulmonary fibrosis, Fujiwara et al.  identified pneumomediastinum on chest CT scans in 5 patients (14.7%). However, they did not assess parenchymal abnormalities at the onset of pneumomediastinum, and assumed that honeycombing pattern and violent cough were predisposing factors for pneumomediastinum.
Our patient had evidence of idiopathic ILD observed several years ago in CT images showing an irregular septal and reticular pattern located in the axial and subpleural interstitium predominantly in the peripheral and basal regions. Reviewing the treatment plan, the treated metastatic lesion was located into the area with higher density of interstitial pattern, the volume receiving at least 20 Gy (V20) was 18% and the mean lung dose was 7.81 Gy (Figure 3-4). These dosimetric parameters are considered in the literature as low risk of pneumonitis after SBRT. To our knowledge, the spontaneous pneumomediastinum and pneumotorax in lung cancer following chemotherapy and radiotherapy may occur due to a variety of mechanisms such as: 1) the rapid tumor lysis and defective tissue repair leading to rupture of a periphereal necrotic pulmonary nodule into the pleural space and/or the bronchus resulting in a bronchopleural fistula and pneumotorax; or 2) the rapid formation of a tumor cavity after radiation therapy with subsequent enlargement and penetration into pleural space. No radiation dose–response effect has been described in the literature, although pneumothorax and pneumomediatinum were not observed in patients who received less than 3000 cGy [14,15]. Chemotherapy also does not appear to correlate with the occurrence of SPT. However, SPT in patients with ILD receiving potentially pneumotoxic chemotherapy, such as chemotherapy-induced interstitial fibrosis and pneumonia, usually SPT is severe, bilateral, and/or recurrent .
In addition to ILD, our patient had other lung conditions associated with PM as to have a metastatic cancer in the lung and to receive pneumotoxic chemotherapy.
Pulmonary toxicities due to gemcitabine have been reported. Dyspnea occurs in approximately 25% of patients treated with gemcitabine, whereas serious pulmonary toxicities are much less common, approximately 0.3% of patients present severe pulmonary adverse effects . Gemcitabine can induce radiation recall reactions  and the elapsed time required for recall reaction after gemcitabine administration range from 3 days to 8 months . Our patient developed pneumomediastinum 2 weeks after gemcitabine administration and 6 months after SBRT treatment and it is difficult to asses the relative input of gemcitabine in the development of pneumomediastinum but a probable synergistic effect between gemcitabine and SBRT could have been responsible for this severe pulmonary toxicity.
Perhaps, the presence in this patient of multiple predisposing factors with the addition of a precipitating factor such as the delivering of an ablative radiation dose have caused the loss of integrity of the alveolar-capillary membrane and consequently the development of pneumomediastinum.
We describe a 52-year-old female with oligometastatic lung disease from squamous-cell urethral carcinoma who was treated with SABR for a solitary metastatic lesion located in the right lower pulmonary lobe. The presence of idiopathic ILD and other identifiable underlying lung conditions were not taken into account as a constraint to prescribe a different total dose or fractionation schedule.
Radiation oncologist should be aware of the potential risk of severe lung toxicity caused by SBRT in patients with ILD, especially when pulmonary toxicity-inducible chemotherapy is administered in a short time interval.
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.
- Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol. 2007;30:637–44.PubMedView ArticleGoogle Scholar
- McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–5.PubMedView ArticleGoogle Scholar
- Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.PubMedView ArticleGoogle Scholar
- Rodríguez-Ruiz ME, San Miguel I, Gil-Bazo I, Perez-Gracia JL, Arbea L, Moreno-Jimenez M, et al. Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review. Radiat Oncol. 2012;7:50.PubMed CentralPubMedView ArticleGoogle Scholar
- Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, et al. Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007;2:21–32.PubMed CentralPubMedView ArticleGoogle Scholar
- Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for ung metastases. J Clin Oncol. 2009;27:1579–84.PubMedView ArticleGoogle Scholar
- Rodrigues G, Lock M, D’Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer: a systematic review. Radiother Oncol. 2004;71:127–38.PubMedView ArticleGoogle Scholar
- Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5.PubMedView ArticleGoogle Scholar
- Roguin A. Rene theophile hyacinthe laënnec (1781–1826): The man behind the stethoscope. Clin Med Res. 2006;4:230–5.PubMed CentralPubMedView ArticleGoogle Scholar
- Newcomb AE, Clarke CP. Spontaneous pneumomediastinum: a benign curiosity or a significant problem? Chest. 2005;128:3298–302.PubMedView ArticleGoogle Scholar
- Iyer VN, Mandrekar JN, Danielson RD, Zubkov AY, Elmer JL, Wijdicks EF. Validity of the FOUR Score Coma Scale in the Medical Intensive Care Unit. Mayo Clin Proc. 2009;84:694–701.PubMed CentralPubMedView ArticleGoogle Scholar
- Galvão FH, Pestana JO, Capelozzi VL. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol. 2010;65:607–10.PubMed CentralPubMedView ArticleGoogle Scholar
- Fujiwara T. Pneumomediastinum in pulmonary fibrosis. Detection by computed tomography. Chest. 1993;104:44–6.PubMedView ArticleGoogle Scholar
- Pezner RD, Horak DA, Sayegh HO, Lipsett JA. Spontaneous pneumothorax in patients irradiated for Hodgkin’s disease and other malignant lymphoma. Int J Radiat Oncol Biol Phys. 1990;18:193–8.PubMedView ArticleGoogle Scholar
- Penniment MG, O’Brien PC. Penumothorax following thoracic radiation therapy for Hodgkin’s disease. Thorax. 1994;49:936–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med. 2009;48(9):665–72.PubMedView ArticleGoogle Scholar
- Chi DC, Brogan F, Turenne I, Zelonis S, Schwartz L, Saif MW. Gemcitabine-induced pulmonary toxicity. Anticancer Res. 2012;32:4147–9.PubMedGoogle Scholar
- Pa F, Bansal R, Schwartz L, et al. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer. 2004;100:1793–9.View ArticleGoogle Scholar
- Jeter MD, Jane PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002;53:394–400.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.